Eflornithine
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Eflornithine: From African Trypanosomiasis to Esotropia
One-Sentence Summary
Eflornithine is an irreversible ornithine decarboxylase (ODC) inhibitor historically used to treat African trypanosomiasis (sleeping sickness), and in topical form to reduce facial hirsutism. The TxGNN model predicts it may be effective for Esotropia, but currently no clinical trials and no literature support this direction — the prediction rests solely on a graph-based statistical association, with no established pharmacological mechanism connecting polyamine synthesis inhibition to extraocular muscle control.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | African trypanosomiasis (sleeping sickness); topical use for facial hirsutism (regulatory filing data not available) |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
A formal, sourced mechanism-of-action record is not currently available for this drug (data gap). Based on known pharmacology referenced in the evidence pack, eflornithine is an irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis. It is clinically used for African trypanosomiasis and, topically, to slow facial hair growth by suppressing polyamine-dependent hair follicle cell activity.
Esotropia is a condition of inward eye deviation, primarily driven by extraocular muscle tone imbalance or neural (cranial nerve) control dysfunction. There is no known biological pathway linking polyamine synthesis inhibition to extraocular muscle innervation or tone regulation. The high TxGNN score most likely reflects a statistical pattern learned from the knowledge graph's structure rather than a genuine pharmacological relationship, and no mechanistic hypothesis in the evidence pack supports this link.
A second predicted indication, neurotrophic keratopathy, was also flagged (TxGNN score 99.38%, rank 6845). Here the mechanistic direction is arguably counterproductive: polyamines support cell proliferation and wound healing, so ODC inhibition could theoretically impair corneal epithelial regeneration rather than help it. This indication is included for transparency but is not the primary focus of this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Eflornithine is currently not marketed in Taiwan, and no license/authorization records are available in this evidence pack (0 total licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or literature evidence for eflornithine in esotropia, and no plausible mechanistic link between ODC/polyamine inhibition and extraocular muscle or neural control. With evidence level L5 (model prediction only), this candidate does not meet the threshold to advance.
To proceed, the following is needed:
- Verified, sourced mechanism-of-action (MOA) data for eflornithine (currently a data gap)
- TFDA-sourced package insert warnings and contraindications (currently a data gap; classified as Blocking for safety pre-screening)
- Preclinical or mechanistic studies exploring any plausible link between polyamine metabolism and ocular motor pathways, if this candidate is to be pursued further
- Ongoing monitoring for newly registered trials or publications on eflornithine in ophthalmic indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.